Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Change in Cash: 2010-2025

Historic Change in Cash for Amicus Therapeutics (FOLD) over the last 14 years, with Sep 2025 value amounting to $31.8 million.

  • Amicus Therapeutics' Change in Cash rose 30.16% to $31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.0 million, marking a year-over-year decrease of 45.87%. This contributed to the annual value of -$33.4 million for FY2024, which is 134.41% down from last year.
  • Latest data reveals that Amicus Therapeutics reported Change in Cash of $31.8 million as of Q3 2025, which was up 240.17% from -$22.7 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Change in Cash ranged from a high of $209.3 million in Q3 2021 and a low of -$139.6 million during Q4 2021.
  • For the 3-year period, Amicus Therapeutics' Change in Cash averaged around $3.7 million, with its median value being -$437,000 (2024).
  • Its Change in Cash has fluctuated over the past 5 years, first spiked by 2,321.49% in 2023, then tumbled by 5,098.40% in 2025.
  • Quarterly analysis of 5 years shows Amicus Therapeutics' Change in Cash stood at -$139.6 million in 2021, then rose by 8.02% to -$128.4 million in 2022, then surged by 87.39% to -$16.2 million in 2023, then fell by 24.14% to -$20.1 million in 2024, then skyrocketed by 30.16% to $31.8 million in 2025.
  • Its Change in Cash stands at $31.8 million for Q3 2025, versus -$22.7 million for Q2 2025 and -$32.0 million for Q1 2025.